abbvie inc. - ABBV

ABBV

Close Chg Chg %
190.34 1.55 0.81%

Pre-Market

191.89

+1.55 (0.81%)

Volume: 3.98M

Last Updated:

Feb 11, 2025, 3:59 PM EDT

Company Overview: abbvie inc. - ABBV

ABBV Key Data

Open

$189.78

Day Range

188.26 - 191.93

52 Week Range

153.59 - 207.32

Market Cap

$336.36B

Shares Outstanding

1.77B

Public Float

1.77B

Beta

0.56

Rev. Per Employee

N/A

P/E Ratio

78.99

EPS

$2.41

Yield

330.01%

Dividend

$1.64

EX-DIVIDEND DATE

Jan 15, 2025

SHORT INTEREST

N/A

AVERAGE VOLUME

6.36M

 

ABBV Performance

1 Week
 
0.65%
 
1 Month
 
9.51%
 
3 Months
 
16.27%
 
1 Year
 
8.08%
 
5 Years
 
103.97%
 

ABBV Analyst Ratings

  • Sell
  • Under
  • Hold
  • Over
  • Buy
Number of Ratings 31
Full Ratings ➔

About abbvie inc. - ABBV

AbbVie, Inc. is a research-based biopharmaceutical company, which engages in the development and sale of pharmaceutical products. It focuses on treating conditions such as chronic autoimmune diseases in rheumatology, gastroenterology, and dermatology, oncology, including blood cancers, virology, hepatitis C virus (HCV) and human immunodeficiency virus (HIV), neurological disorders, such as Parkinson's, metabolic, comprising thyroid disease and complications associated with cystic fibrosis, pain associated with endometriosis, and other serious health conditions. The company was founded on October 19, 2011 and is headquartered in North Chicago, IL.

ABBV At a Glance

AbbVie, Inc.
1 North Waukegan Road
North Chicago, Illinois 60064-6400
Phone 1-847-932-7900 Revenue 56.33B
Industry Pharmaceuticals: Major Net Income 4.28B
Sector Health Technology 2024 Sales Growth 3.711%
Fiscal Year-end 12 / 2025 Employees N/A
View SEC Filings

ABBV Valuation

P/E Current 78.992
P/E Ratio (with extraordinary items) N/A
P/E Ratio (without extraordinary items) 73.646
Price to Sales Ratio 5.593
Price to Book Ratio N/A
Price to Cash Flow Ratio N/A
Enterprise Value to EBITDA N/A
Enterprise Value to Sales N/A
Total Debt to Enterprise Value N/A

ABBV Efficiency

Revenue/Employee N/A
Income Per Employee N/A
Receivables Turnover N/A
Total Asset Turnover N/A

ABBV Liquidity

Current Ratio N/A
Quick Ratio N/A
Cash Ratio N/A

ABBV Profitability

Gross Margin 83.923
Operating Margin 32.515
Pretax Margin 6.596
Net Margin 7.594
Return on Assets N/A
Return on Equity N/A
Return on Total Capital N/A
Return on Invested Capital N/A

ABBV Capital Structure

Total Debt to Total Equity N/A
Total Debt to Total Capital N/A
Total Debt to Total Assets N/A
Long-Term Debt to Equity N/A
Long-Term Debt to Total Capital N/A
  • Income Statement
  • Balance Sheet
  • Cash Flow Statement

Annual Financials for Abbvie Inc. - ABBV

Collapse All in section
All values USD millions. 2021 2022 2023 2024 5-year trend
Sales/Revenue
56.20B 58.05B 54.32B 56.33B
Sales Growth
+22.69% +3.30% -6.44% +3.71%
Cost of Goods Sold (COGS) incl D&A
17.14B 16.45B 16.65B 9.06B
COGS excluding D&A
- - - -
-
Depreciation & Amortization Expense
- 8.52B 8.47B 8.70B
Depreciation
- 803.00M 778.00M 752.00M
Amortization of Intangibles
7.72B 7.69B 7.95B 7.62B
COGS Growth
+21.43% -4.08% +1.25% -45.60%
Gross Income
39.05B 41.61B 37.67B 47.28B
Gross Income Growth
+23.25% +6.54% -9.47% +25.51%
Gross Profit Margin
+69.49% +71.67% +69.35% +83.92%
2021 2022 2023 2024 5-year trend
SG&A Expense
19.30B 19.01B 19.59B 21.34B
Research & Development
6.98B 6.49B 7.04B 8.06B
Other SG&A
12.32B 12.52B 12.55B 13.29B
SGA Growth
+20.23% -1.54% +3.05% +8.98%
Other Operating Expense
- - - 7.62B
-
Unusual Expense
4.08B 7.26B 10.53B 12.97B
EBIT after Unusual Expense
15.66B 15.34B 7.55B 5.34B
Non Operating Income/Expense
(226.00M) 485.00M 1.06B 510.00M
Non-Operating Interest Income
- 39.00M 186.00M 540.00M
Equity in Earnings of Affiliates
- - - -
-
Interest Expense
2.45B 2.35B 2.36B 2.14B
Interest Expense Growth
-2.78% -4.21% +0.60% -9.49%
Gross Interest Expense
2.45B 2.35B 2.36B 2.14B
Interest Capitalized
- - - -
-
Pretax Income
12.99B 13.48B 6.25B 3.72B
Pretax Income Growth
+282.25% +3.76% -53.62% -40.54%
Pretax Margin
+23.11% +23.21% +11.51% +6.60%
Income Tax
1.44B 1.63B 1.38B (570.00M)
Income Tax - Current - Domestic
- 1.99B 2.65B 3.27B
Income Tax - Current - Foreign
- 351.00M 916.00M 994.00M
Income Tax - Deferred - Domestic
- (839.00M) (1.51B) (2.32B)
Income Tax - Deferred - Foreign
- (59.00M) (419.00M) (565.00M)
Income Tax Credits
- - - -
-
Equity in Earnings of Affiliates
- - - -
-
Other After Tax Income (Expense)
- (74.00M) (54.00M) (43.00M)
Consolidated Net Income
11.47B 11.79B 4.83B 4.29B
Minority Interest Expense
7.00M 9.00M 10.00M 8.00M
Net Income
11.47B 11.78B 4.82B 4.28B
Net Income Growth
+151.71% +2.74% -59.09% -11.24%
Net Margin Growth
+20.41% +20.29% +8.87% +7.59%
Extraordinaries & Discontinued Operations
- - - -
-
Discontinued Operations
- - - -
-
Net Income After Extraordinaries
11.47B 11.78B 4.82B 4.28B
Preferred Dividends
- - - -
-
Net Income Available to Common
11.47B 11.78B 4.82B 4.28B
EPS (Basic)
- 6.4791 6.6527 2.7262
EPS (Basic) Growth
- +137.07% +2.68% -59.02%
Basic Shares Outstanding
- 1.77B 1.77B 1.77B
EPS (Diluted)
6.4536 6.6266 2.7186 2.4129
EPS (Diluted) Growth
+136.99% +2.68% -58.97% -11.24%
Diluted Shares Outstanding
1.78B 1.78B 1.77B 1.77B
EBITDA
- 28.27B 31.07B 26.78B
EBITDA Growth
- +27.91% +9.90% -13.80%
EBITDA Margin
- +50.31% +53.52% +49.30%

Snapshot

Average Recommendation OVERWEIGHT Average Target Price 206.64
Number of Ratings 31 Current Quarters Estimate 2.517
FY Report Date 03 / 2025 Current Year's Estimate 12.272
Last Quarter’s Earnings 2.16 Median PE on CY Estimate N/A
Year Ago Earnings 10.12 Next Fiscal Year Estimate 13.922
Median PE on Next FY Estimate N/A

Earnings Per Share

This Quarter Next Quarter This Fiscal Next Fiscal
# of Estimates 17 17 24 24
Mean Estimate 2.52 3.07 12.27 13.92
High Estimates 2.70 3.32 12.67 14.96
Low Estimate 2.46 2.93 12.01 13.26
Coefficient of Variance 2.24 3.18 1.10 3.42

Analysts Recommendations

Current 1 Month Ago 3 Months Ago
BUY 18 18 20
OVERWEIGHT 2 2 2
HOLD 11 11 10
UNDERWEIGHT 0 0 0
SELL 0 0 0
MEAN Overweight Overweight Overweight

Insider Actions for Abbvie Inc. - ABBV

Date Name Shares Transaction Value
Jan 6, 2025 Robert J. Alpern Director 9,788 Grant, award or other acq pursuant to Rule 16b-3(d) 0.00
Jan 6, 2025 Susan E. Quaggin Director 401 Grant, award or other acq pursuant to Rule 16b-3(d) 0.00
Jan 6, 2025 Edward J. Rapp Director 26,976 Grant, award or other acq pursuant to Rule 16b-3(d) 0.00
Jul 3, 2024 Richard A. Gonzalez CHAIRMAN OF THE BOARD AND CEO; Director 513,099 Bona fide gift 0.00
May 8, 2024 Rebecca Brown Roberts Director 12,525 Grant, award or other acq pursuant to Rule 16b-3(d) 0.00
May 8, 2024 Jennifer L. Davis Director 1,322 Grant, award or other acq pursuant to Rule 16b-3(d) 0.00
May 8, 2024 Melody B. Meyer Director 15,295 Grant, award or other acq pursuant to Rule 16b-3(d) 0.00
May 8, 2024 Roxanne Schuh Austin Director 37,255 Grant, award or other acq pursuant to Rule 16b-3(d) 0.00
May 8, 2024 Brett J. Hart Director 18,269 Grant, award or other acq pursuant to Rule 16b-3(d) 0.00
May 8, 2024 William H. L. Burnside Director 25,755 Grant, award or other acq pursuant to Rule 16b-3(d) 0.00
May 8, 2024 Thomas C. Freyman Director 125,548 Grant, award or other acq pursuant to Rule 16b-3(d) 0.00
May 8, 2024 Glenn Fletcher Tilton Director 50,361 Grant, award or other acq pursuant to Rule 16b-3(d) 0.00
May 8, 2024 Frederick H. Waddell Director 27,755 Grant, award or other acq pursuant to Rule 16b-3(d) 0.00
Mar 21, 2024 Jeffrey Ryan Stewart EVP, CHIEF COMMERCIAL OFFICER 93,780 Open market or private sale of non-derivative or derivative security Non-derivative transaction at $178.85 per share 16,772,553.00
Mar 21, 2024 Jeffrey Ryan Stewart EVP, CHIEF COMMERCIAL OFFICER 88,681 Open market or private sale of non-derivative or derivative security Non-derivative transaction at $179.03 per share 15,876,559.43
Mar 21, 2024 Jeffrey Ryan Stewart EVP, CHIEF COMMERCIAL OFFICER 119,890 Exercise or conversion of derivative security exempted pursuant to Rule 16b-3 Non-derivative transaction at $61.36 per share 7,356,450.40
Mar 21, 2024 Jeffrey Ryan Stewart EVP, CHIEF COMMERCIAL OFFICER N/A Exercise or conversion of derivative security exempted pursuant to Rule 16b-3 0.00
Mar 21, 2024 Jeffrey Ryan Stewart EVP, CHIEF COMMERCIAL OFFICER 60,941 Open market or private sale of non-derivative or derivative security Non-derivative transaction at $178.69 per share 10,889,547.29
Mar 6, 2024 Timothy J. Richmond EVP, CHIEF HR OFFICER 89,517 Exercise or conversion of derivative security exempted pursuant to Rule 16b-3 Non-derivative transaction at $61.36 per share 5,492,763.12
Mar 6, 2024 Timothy J. Richmond EVP, CHIEF HR OFFICER 13,837 Open market or private sale of non-derivative or derivative security Non-derivative transaction at $177.71 per share 2,458,973.27

Abbvie Inc. in the News